1. What Is the Heart Failure Management Market?
The Heart Failure Management Market covers pharmaceutical and device therapies, remote monitoring platforms, and disease management programmes for heart failure including HFrEF, HFmrEF, and HFpEF subtypes. Heart failure management encompasses GDMT pharmacotherapy, CRT-D devices, LVAD left ventricular assist devices, CardioMEMS hemodynamic monitoring, and remote digital heart failure management platforms. Market dynamics reflect SGLT2 inhibitor and GLP-1 receptor agonist expanding GDMT revenue, CardioMEMS remote monitoring demonstrating hospitalisation reduction, and HFpEF treatment options expanding beyond therapy-refractory subtype.
2. Heart Failure Management Market Size & Forecast
3. Emerging Technologies
- Quadruple GDMT therapy initiation protocols starting all four HF medication classes within 90 days of diagnosis are advancing as guideline implementation tools. Growing adoption at HF programmes is driven by outcomes improvement from early comprehensive GDMT start.
- AI heart failure progression prediction platforms identifying high-risk decompensation before hospitalisation are advancing. Growing adoption at HF remote monitoring programmes is driven by hospitalisation avoidance requirements.
- Wearable HF congestion monitoring using bioimpedance or seismocardiography for daily fluid status tracking are advancing. Growing adoption is driven by between-visit HF congestion detection requirements.
- HFpEF precision medicine phenotyping platforms stratifying HFpEF into treatable subgroups are advancing. Growing adoption at HFpEF research programmes is driven by clinical trial enrolment precision requirements.
Comparable technologies are influencing adjacent market segments in similar ways. Read more in our Electrophysiology Lab Market.
4. Key Market Opportunity
The largest addressable opportunity within the Heart Failure Management Market is the SGLT2 inhibitor pharmacotherapy sub-market, where GDMT fourth-pillar adoption across 60 million global HF patients creates multi-billion-dollar annual pharmaceutical revenue. GLP-1 receptor agonist HFpEF treatment creates a premium pharmacotherapy opportunity as tirzepatide SURMOUNT-HF positions GLP-1 as first effective HFpEF therapy. CardioMEMS haemodynamic monitoring creates a device revenue opportunity as high-risk HF hospitalisation reduction demonstrates payer ROI. Asia Pacific HF management creates geographic expansion as Chinese and Indian HF programme guideline implementation grows.
5. Top Companies in the Heart Failure Management Market
The following organisations hold leading positions in the Heart Failure Management Market. The full report provides revenue share, SWOT analysis, and competitive benchmarking for each player.
- AstraZeneca (Farxiga SGLT2)
- Eli Lilly (Tirzepatide HF)
- Novartis (Entresto ARNI)
- Abbott (CardioMEMS, CRT-D)
- Medtronic (LVAD, CRT-D)
- Boston Scientific (CRT-D)
- Abiomed (LVAD)
- CareDx
- Corvia Medical
- Vectorious Medical
6. Market Segmentation
The Heart Failure Management Market is analysed across 4 segmentation dimensions. Revenue data, growth rates, and competitive intensity by sub-segment are available in the full report.
| Segmentation | Sub-Segments |
|---|---|
| By Therapy | GDMT Pharmacotherapy CRT-D Device LVAD Haemodynamic Monitor Remote Management |
| By HF Subtype | HFrEF EF Below 40% HFmrEF 40-49% HFpEF EF Above 50% |
| By Setting | Inpatient Outpatient HF Clinic Home |
| By Geography | North America The U.S. Canada Europe The UK Germany France Italy Spain Denmark Netherlands Finland Sweden Norway Russia Austria Poland Rest of Europe Asia Pacific China Japan India South Korea Australia Indonesia Vietnam Philippines Singapore Taiwan Thailand Rest of Asia Pacific Latin America Brazil Mexico Argentina Rest of South America Middle East and Africa GCC Countries Israel South Africa Rest of Middle East and Africa |
7. Key Market Trends (2026–2034)
Three major forces are shaping the Heart Failure Management Market trajectory over the forecast period:
AstraZeneca Farxiga SGLT2 Inhibitor Achieves USD 2.5 Billion HF Revenue as Standard Fourth Pillar GDMT.AstraZeneca dapagliflozin achieving USD 2.5 billion annual heart failure indication revenue in 2024 demonstrates SGLT2 inhibitor establishing as the fourth pillar of guideline-directed medical therapy. DAPA-HF and EMPEROR-Reduced trials demonstrating 25 percent cardiovascular death and worsening HF reduction establish SGLT2 inhibitor class benefit across HFrEF.
Eli Lilly Tirzepatide SURMOUNT-HF Trial Demonstrates HFpEF Weight Loss and Functional Benefit.Eli Lilly tirzepatide SURMOUNT-HF demonstrating 38 percent improvement in 6-minute walk distance and 50 percent HF hospitalisation reduction in obese HFpEF in 2024 demonstrates dual agonist HFpEF efficacy. Tirzepatide SURMOUNT-HF creating the first effective pharmacotherapy for obese HFpEF demonstrates treatment expansion into the most prevalent HF subtype.
Abbott CardioMEMS HF Sensor Demonstrates 36 Percent Hospitalisation Reduction in High-Risk HF.Abbott CardioMEMS pulmonary artery pressure sensor achieving 36 percent HF hospitalisation reduction in CHAMPION trial long-term follow-up through 2024 demonstrates haemodynamic remote monitoring commercial evidence. CardioMEMS achieving 70,000 cumulative implants in high-risk HF demonstrates implantable haemodynamic monitoring at commercial scale.
For related market intelligence, see the Cardiac Implantable Electronic Device Market.
8. Segmental Analysis
By therapy, the GDMT Pharmacotherapy segment dominated the Heart Failure Management Market in 2025. Representing the largest revenue category as SGLT2, ARNI, beta-blocker, and MRA quadruple therapy creates multi-drug annual prescription revenue. The GLP-1 Receptor Agonist HFpEF Therapy segment is the fastest-growing category, advancing as tirzepatide SURMOUNT-HF drives adoption in the 50 percent of HF patients with preserved ejection fraction.
By HF subtype, the HFrEF segment dominated the Heart Failure Management Market in 2025, as heart failure with reduced ejection fraction represents the best-evidenced and most-treated subtype with established quadruple medical therapy and device therapy guidelines. HFpEF is the fastest-growing subtype category, driven by SGLT2 inhibitor approval for HFpEF and increasing diagnosis of preserved ejection fraction heart failure in ageing populations.
By care setting, the Outpatient HF Clinic segment dominated the Heart Failure Management Market in 2025, as dedicated heart failure specialist programmes managing complex patients with volume optimisation and guideline therapy titration generate the highest care management revenue. Home-based management is the fastest-growing setting category, driven by remote haemodynamic monitoring, telehealth follow-up, and hospital-at-home heart failure programme adoption.
9. Regional Analysis
Regional demand patterns across the Heart Failure Management Market reflect differences in regulation, technological maturity, and capital investment.
Largest Market Share
North America accounted for the largest share of the Heart Failure Management Market in 2025, holding 44.8% of the global market. Cardiologists, heart failure specialty programmes, and integrated health systems are deploying advanced heart failure management platforms integrating remote monitoring, haemodynamic sensing, and care coordination to reduce hospitalisations. CMS heart failure quality metrics, Medicare readmission penalty programmes, and growing value-based care heart failure episode payment models are encouraging cardiac programmes to invest in advanced heart failure management capabilities. High heart failure prevalence, established cardiology infrastructure, and strong demand for hospital readmission reduction are generating regional heart failure management platform demand.
Highest CAGR Region
Asia Pacific is expected to register the highest CAGR of 12.82% during the forecast period. Cardiology programmes, cardiac rehabilitation centres, and heart failure disease management companies across China, Japan, South Korea, and India are deploying advanced heart failure monitoring and management platforms as cardiovascular disease burden increases. Growing cardiovascular disease prevalence from hypertension, diabetes, and obesity in ageing populations and increasing demand for remote heart failure monitoring are encouraging adoption. Rising physician awareness of advanced heart failure therapies and increasing deployment of implantable haemodynamic monitors are generating Asian heart failure management demand.
10. Full Report with Exclusive Insights
The complete published market report includes an in-depth analysis of market dynamics, industry trends, competitive landscape, regional outlook, and future growth opportunities. The study provides detailed market sizing and forecasts across key segments and geographies, along with comprehensive insights into drivers, restraints, opportunities, challenges, technological advancements, regulatory landscape, and evolving consumer and industry trends. The report also features company profiles, strategic developments, market share analysis, and actionable recommendations to support informed business decision-making. Additionally, the syndicated report package typically includes forecast datasets, charts and figures, research methodology, and analyst support for strategic interpretation and planning.
Advanced Strategic & Custom Intelligence
In addition to the standard syndicated report package, TrendX Insights can provide the following advanced strategic analyses and customized intelligence solutions for any market:
Standard Report Coverage
- • Competitor Analysis
- • Country Trade Analysis
- • Import & Export Analysis
- • Porter’s Five Forces Analysis
- • SWOT Analysis by Companies
- • TrendX Insights Quadrant Positioning
- • Pricing Analysis
- • Detailed Macro-Economic Indicators Assessment
- • List of Raw Material Suppliers
- • Regulatory Framework Assessment
- • Supply Chain Resilience Mapping
- • Value Chain Analysis
- • Technology Adoption Trends and Innovation Tracking
- • Custom Company Profiling and Benchmarking
Exclusive Sections With Additional Cost
- • Agentic AI Readiness Score
- • TAM, SAM, and SOM Analysis
- • AI Act & Privacy Compliance Audit
- • Channel Partner Ecosystem Mapping
- • China + 1 Strategy Analysis
- • Circular Economy Opportunities Assessment
- • Competitor Benchmarking KPI Analysis
- • Country-Level Opportunity Mapping
- • Digital Maturity Matrix
- • Ecosystem Interdependency Mapping
- • ESG & Decarbonization Roadmap
- • Geopolitical Friction Scorecard
- • Geopolitical Risk Assessment
- • Humanoid Workforce Impact Analysis
- • Investment Heatmap
- • List of Distributors and Channel Partners
- • Market Entry Strategy Assessment
- • Mergers & Acquisitions (M&A) Analysis
- • Patent & Intellectual Property (IP) Analysis
- • Pilot Project Analysis
- • Potential High-Growth Region/Country Investment Assessment
- • Product Comparison Analysis
- • Product Revenue Analysis
- • R&D Investment Analysis in Emerging Technologies
- • Raw Material Scarcity Forecast
Note: For highly customized requirements, deeper strategic assessments, company-specific intelligence, or tailored consulting support, please contact TrendX Insights.
Full Report with Exclusive Insights
Available to clients on request
Explore Our Published Reports Library
This page covers market-level data estimates. For comprehensive published research reports including full methodology, primary data, and detailed company profiles, browse the TrendX Insights Published Reports Library.
Visit Published Reports Library ›11. Related Market Reports
Frequently Asked Questions
The Heart Failure Management Market was valued at USD 12.43 Bn in 2025 and is projected to reach USD 31.29 Bn by 2034, growing at a CAGR of 10.8% over the 2026–2034 forecast period.
The Heart Failure Management Market is projected to grow at a CAGR of 10.8% from 2026 to 2034.
North America accounted for the largest share of the Heart Failure Management Market in 2025, holding 44.8% of the global market.
The leading companies in the Heart Failure Management Market include AstraZeneca (Farxiga SGLT2), Eli Lilly (Tirzepatide HF), Novartis (Entresto ARNI), Abbott (CardioMEMS, CRT-D), Medtronic (LVAD, CRT-D), Boston Scientific (CRT-D), Abiomed (LVAD), CareDx, Corvia Medical, Vectorious Medical.
Astrazeneca farxiga sglt2 inhibitor achieves usd 2.5 billion hf revenue as standard fourth pillar gdmt.
By therapy, the GDMT Pharmacotherapy segment dominated the Heart Failure Management Market in 2025.
How to Order
Choose Your Package
Condensed edition of this study for students, researchers and academic institutions.
- Condensed edition of the full study
- For students, researchers & academic institutions
- Valid student ID or institutional email required
- Educational, non-commercial use only
The competitive landscape, including key market participants, company size, market positioning, and comparative competitive standing.
- 15 in-depth company profiles
- Company overview
- Product and brand portfolio mapped per company
- Revenue for the last 3 FYs with key financial metrics
- Segmental revenue and regional revenue breakdown
- Market presence, key geographies & end-use industries
- Recent developments
- Key capabilities, differentiators & strategic positioning
- SWOT Analysis
- 15-company market share analysis
- 2025 market share by company
- Company revenue in USD
- Competitive quadrant positioning
- Product portfolio comparison
The complete forecast model, including every study table, is provided in clean, formula-ready Excel format across 3 segmentation axes. Select the geographic coverage required for your analysis.
- One country, broken out across 3 segmentation axes
- 2025 base year, 2026–2034 forecast, CAGR per line
- Excel workbook
- Region totals plus every country inside that region
- All axes, all years, CAGR per line
- Cross-country comparison sheet included
- Excel workbook
- Every forecast table in the study
- Global, regional and country views in one workbook
- Segment share and CAGR pivots included
- Excel workbook
The full syndicated study. Every chapter, every region, every country, plus the complete Excel model, methodology and appendix.
- Executive summary, market scope & segmental snapshot
- Market dynamics: drivers, restraints, opportunities, challenges
- Quantitative analysis across 3 segmentation axes
- Regional analysis
- Competitive landscape, market share & company revenue mapping
- Includes the full Global Excel Data Pack
- Complete research methodology, assumptions & appendix
TAM/SAM/SOM sizing, M&A target screening, patent & IP analysis, supply-chain resilience mapping, ESG roadmaps and other bespoke strategic work.
- TAM / SAM / SOM sizing
- M&A target screening
- Patent & IP analysis
- Supply-chain resilience mapping
- ESG roadmaps & other bespoke strategic work
Not sure which package fits? Tell us the decision you are making and an analyst will recommend the smallest package that answers it. Talk to an analyst.
Ordering Process
Our process is designed to be transparent and risk-free for buyers, with a 20% upfront model and full delivery before the balance payment.